CD44 and hepatocellular carcinoma: According to findings by Hwang et al., they showed that exosomal miR-6126 restores sorafenib sensitivity in resistant hepatocellular carcinoma by targeting CD44 and HK2, making it a promising therapeutic target to overcome drug resistance [197].